Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to sofetabart mipitecan (LY4170156) for the treatment of adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received prior bevacizumab and mirvetuximab soravtansine, if eligible. Sofetabart mipitecan is a […] The post Lilly’s sofetabart mipitecan receives U.S. FDA’s Breakthrough Therapy designation for the treatment of certain patients with platinum-resistant ovarian cancer appeared first on Web-Release.

    The Family Care Authority (FCA) has announced the launch of the second episode of the “Wateen” Podcast, an awareness-driven initiative aimed at strengthening community awareness and supporting family cohesion and… The post Family Care Authority Launches Second “Wateen” Podcast Episode: “Reassurance Begins at Home: How Can We Strengthen Family Resilience During Difficult Times?” appeared first on Web-Release.